Crinetics Pharmaceuticals, Inc.

NasdaqGS:CRNX Stock Report

Market Cap: US$5.2b

Crinetics Pharmaceuticals Valuation

Is CRNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CRNX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CRNX's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRNX?

Key metric: As CRNX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CRNX. This is calculated by dividing CRNX's market cap by their current book value.
What is CRNX's PB Ratio?
PB Ratio6.2x
BookUS$832.98m
Market CapUS$5.20b

Price to Book Ratio vs Peers

How does CRNX's PB Ratio compare to its peers?

The above table shows the PB ratio for CRNX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average10.2x
IONS Ionis Pharmaceuticals
8.1x32.9%US$5.4b
ISEE IVERIC bio
11.6x59.0%US$5.5b
VKTX Viking Therapeutics
6.4x-1.8%US$5.9b
BHVN Biohaven
14.6x21.6%US$4.6b
CRNX Crinetics Pharmaceuticals
6.2x9.0%US$5.2b

Price-To-Book vs Peers: CRNX is good value based on its Price-To-Book Ratio (6.2x) compared to the peer average (9.7x).


Price to Book Ratio vs Industry

How does CRNX's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$554.58m
IMAB I-Mab
0.4x1.8%US$76.59m
ACET Adicet Bio
0.4x6.7%US$74.16m
MGX Metagenomi
0.3x-23.2%US$70.73m
CRNX 6.2xIndustry Avg. 1.9xNo. of Companies81PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CRNX is expensive based on its Price-To-Book Ratio (6.2x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is CRNX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRNX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CRNX's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRNX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$56.06
US$73.29
+30.7%
17.0%US$97.00US$54.00n/a14
Nov ’25US$56.69
US$70.07
+23.6%
18.3%US$97.00US$48.00n/a14
Oct ’25US$51.92
US$69.21
+33.3%
19.0%US$97.00US$48.00n/a14
Sep ’25US$53.06
US$69.21
+30.4%
19.0%US$97.00US$48.00n/a14
Aug ’25US$52.07
US$68.00
+30.6%
20.3%US$97.00US$48.00n/a14
Jul ’25US$46.07
US$67.50
+46.5%
21.4%US$97.00US$47.00n/a14
Jun ’25US$44.41
US$65.07
+46.5%
20.5%US$97.00US$47.00n/a14
May ’25US$45.05
US$56.86
+26.2%
16.7%US$80.00US$40.00n/a14
Apr ’25US$46.53
US$56.86
+22.2%
16.7%US$80.00US$40.00n/a14
Mar ’25US$46.03
US$51.23
+11.3%
16.3%US$65.00US$35.00n/a13
Feb ’25US$37.21
US$47.67
+28.1%
15.7%US$62.00US$35.00n/a12
Jan ’25US$35.58
US$47.27
+32.9%
17.5%US$62.00US$35.00n/a11
Dec ’24US$32.74
US$46.30
+41.4%
18.2%US$57.00US$33.00n/a10
Nov ’24US$29.55
US$47.89
+62.1%
17.5%US$60.00US$33.00US$56.699
Oct ’24US$29.74
US$48.11
+61.8%
17.6%US$60.00US$33.00US$51.929
Sep ’24US$17.44
US$43.22
+147.8%
18.9%US$57.00US$32.00US$53.069
Aug ’24US$19.45
US$47.13
+142.3%
16.6%US$57.00US$35.00US$52.078
Jul ’24US$18.02
US$47.13
+161.5%
16.6%US$57.00US$35.00US$46.078
Jun ’24US$21.85
US$45.78
+109.5%
18.2%US$57.00US$35.00US$44.419
May ’24US$20.50
US$45.56
+122.2%
18.5%US$57.00US$35.00US$45.059
Apr ’24US$16.06
US$44.38
+176.3%
17.7%US$57.00US$35.00US$46.538
Mar ’24US$19.64
US$41.50
+111.3%
16.3%US$55.00US$35.00US$46.036
Feb ’24US$20.00
US$43.17
+115.8%
17.0%US$55.00US$35.00US$37.216
Jan ’24US$18.30
US$43.50
+137.7%
17.6%US$55.00US$35.00US$35.586
Dec ’23US$17.57
US$43.50
+147.6%
17.6%US$55.00US$35.00US$32.746
Nov ’23US$18.50
US$42.67
+130.6%
15.4%US$52.00US$35.00US$29.556

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies